Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continu-ously striking with an unpredictable evolution. Despite the success in vaccine pro-duction and mass vaccination programs, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candi-date coded PHH-1V, based on a heterodimer fusion protein comprising the RBD domain of two SARS-CoV-2 variants. Here, we report data on the efficacy, safety, and immunogenicity of PHH-1V in cynomolgus macaques. PHH-1V prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing anti-bodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, PHH-1V vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respiratory tract after an experimental infection. These results highlight the potential use of the PHH-1V vaccine in humans, currently undergo-Phase III clinical trials.

Automated summary

SARS-CoV-2 emerged in December 2019 and continues to spread, necessitating the development of accessible second-generation vaccines. The PHH-1V vaccine candidate, previously developed, shows efficacy in cynomolgus macaques by inducing high levels of antibodies and cellular immune response. Vaccination with PHH-1V prevents viral replication and reduces viral load in respiratory tracts after experimental infection, suggesting its potential use in humans.